Forecasting Stories

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#689CFD;color: #ffffff;font-size:1.1em;;'>CP</div>
  over a month ago at Macroaxis 
By Achuva Shats
The essential objective of this story is to break down our current position on COUNTRYWIDE for shareholders considering to short it. We will discuss why COUNTRYWIDE PLC shareholders may still consider a stake in the business.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;;'>SS</div>
  over a month ago at Macroaxis 
By Gabriel Shpitalnik
The underlying reasoning behind this short post is to sum up Sky Solar as an investment oportunity for September. We will discuss why recent Sky Solar price moves suggest a bounce in September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;;'>DRA</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Digirad Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to increase significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 4.23 Million. The current year Average Equity is expected to grow to about 29.3 M, whereas Free Cash Flow is forecasted to decline to (4.7 M). The fundamental objective of this short story is to break down our forecasting of Digirad for shareholders. We will try to forecast Digirad outlook for September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#82ADFD;color: #ffffff;font-size:1.1em;;'>UF</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
The primary aim of this article is to break down Unique potential for September. We are going to analyze if Unique Fabricating is reasonably priced going into September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;;'>VER</div>
  over a month ago at Macroaxis 
By Achuva Shats
Veru Total Assets Per Share are comparatively stable at the moment as compared to the past year. Veru reported Total Assets Per Share of 0.74 in 2019. Quick Ratio is likely to gain to 0.31 in 2020, whereas Long Term Debt to Equity is likely to drop 0.07 in 2020. The rationale behind this perspective is to give private investors our take on Veru future value. We will break down the reasons why it could be a game-changer for Veru private investors.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>CB</div>
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Cornerstone Building Tangible Asset Value is relatively stable at the moment as compared to the past year. Cornerstone Building reported last year Tangible Asset Value of 2.48 Billion. As of 08/11/2020, Working Capital is likely to grow to about 641.7 M, while Market Capitalization is likely to drop slightly above 1.1 B. The fundamental reasoning behind this short post is to break down our forecasting of Cornerstone for retail investors. We will try to forecast Cornerstone Building outlook for September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;;'>MA</div>
  over a month ago at Macroaxis 
By Achuva Shats
Macerich Net Income Per Employee is projected to decrease significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 131,370. The current year Average Assets is expected to grow to about 10 B, whereas Revenue Per Employee is forecasted to decline to about 1.1 M. This short post will go over Macerich as a possible investment alternative for your portfolios. We will provide a perspective on Macerich future direction.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>SS</div>
  over a month ago at Macroaxis 
By Ellen Johnson
Safeguard Scientifics Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at 3.08 Million. The current year Average Equity is expected to grow to about 211 M, whereas Earnings before Tax are forecasted to decline to (73.9 M). Today's short post will digest Safeguard Scientifics as your potential position. We will discuss the question of why shareholders should continue to be confident in Safeguard Scientifics outlook.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>OS</div>
  over a month ago at Macroaxis 
By Ellen Johnson
ON Semiconductor Calculated Tax Rate is quite stable at the moment as compared to the past year. The company's current value of Calculated Tax Rate is estimated at 24.46. PPandE Turnover is expected to rise to 2.67 this year, although the value of Average Assets will most likely fall to about 7.1 B. The fundamental goal of this short thesis is to break down our forecasting of ON Semiconductor for institutional investors. We will try to forecast ON Semiconductor outlook for September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;;'>NB</div>
  over a month ago at Macroaxis 
By Achuva Shats
NORTHWEST BIOTHERAPEUTICS PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.0161. Accounts Payable Turnover is expected to rise to 0.0217 this year, although the value of Net Income Per Employee will most likely fall to (6.2 M). The goal of this thesis is to forecast a future value of NORTHWEST BIOTHERAPEUTICS using technical analysis. What exactly are NORTHWEST BIOTHERAPEUTICS institutional investors should expect in September?